{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-24-009003","form_type":"8-K/A","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.034987+00:00","generated_at":"2026-05-31T16:51:16.691024+00:00","sec_items":["2.06","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix expects $50M non-cash impairment on decommissioned ADC facility in Q2 2024","bullets":["Non-cash impairment charge of ~$50M to be recognized in Q2 2024 financial statements.","Facility is a 45,000 sq ft bio-safety level-2 plant in Dartmouth, MA, previously intended for live-virus vaccine manufacturing.","Impairment assumes general industrial use, not GMP; equipment appraised; brokerage firm retained to find buyer.","Company states impairment will not affect future operations, liquidity, or cash flows.","Decommissioning aligns with strategic focus on Tonmya (TNX-102 SL) for fibromyalgia."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-24-009003","json":"https://secwatch.observer/filing/0001999371-24-009003.json","markdown":"https://secwatch.observer/filing/0001999371-24-009003.md","text":"https://secwatch.observer/filing/0001999371-24-009003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/0001999371-24-009003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/tnxp-8ka_072424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:51:16.691024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3dceeb4fb976bc0d6f47ac4ed98228bdb08c89d8","claim":"Tonix Pharmaceuticals Holding Corp. announced a impairment with charges of approximately $50 million affecting Advanced Development Center in Dartmouth, Massachusetts.","evidence_excerpt":"the Company expects that the financial statements for the quarter ended June 30, 2024 will reflect a non-cash impairment in the amount of approximately $50 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/0001999371-24-009003-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"approximately $50 million"},{"label":"Affected area","value":"Advanced Development Center in Dartmouth, Massachusetts"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}